CompletedPhase 2

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

United States156 participantsStarted 2019-12-02

Plain-language summary

The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects or the subject's legally acceptable representatives who sign a written informed consent form prior to the initiation of any study procedures.
✓. Subjects with hyperuricemia and a history or presence of gout per American College of Rheumatology (ACR) criteria.

Exclusion criteria

✕. Subjects with secondary hyperuricemia (e.g., due to myeloproliferative disorder, or organ transplant).
✕. Subjects experiencing an active acute gout attack within 3 weeks prior to screening (Visit 1).

What they're measuring

Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84

Timeframe: Day 84

Trial details

NCT IDNCT03934099

SponsorLG Chem

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-05-03

Results submitted2025-10-29

View on ClinicalTrials.gov More Gout trials